[{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Announces an Investigator-Initiated Study of DSUVIA\u00ae in Orthopedic Patients in the Perioperative Setting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"U.S. Army","pharmaFlowCategory":"D","amount":"$3.6 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Awarded U.S. Army Contract for DSUVIA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Aguettant","pharmaFlowCategory":"D","amount":"$55.0 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Enters into Licensing Agreement for DZUVEO\u00ae in Europe and In-licensing Agreement for Two Products in the U.S.","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Lowell Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals to Acquire Lowell Therapeutics and Reports Third Quarter 2021 Financial Results","therapeuticArea":"Hematology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Undisclosed"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Publication of Clinical Data Finding Potential Benefits of Nafamostat Compared to Regional Citrate for Anticoagulation of the Dialysis Circuit","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Upcoming Podium Presentation on Use of DSUVIA\u00ae for Plastic Surgery Procedures at The Aesthetic Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Minimal Side Effects and Short Recovery Time Reported for DSUVIA\u00ae-Treated Patients: Plastic Surgery Podium Presentation at The Aesthetic Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Publication of Results from an Investigator-Initiated Trial on Sufentanil Sublingual Tablet (SST) Compared to Standard Intravenous Opioids during Plastic Surgery Procedures Performed under General Anesthesia","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Provides Update on Reduced FDA REMS Requirements Related to DSUVIA\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at the ANESTHESIOLOGY 2022 Annual Meeting","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Presentation of Investigator-Initiated Trial Results Comparing AcelRx's Sufentanil Sublingual Tablet (SST) Versus Intravenous Opioids for Postoperative Pain at the ANESTHESIOLOGY\u00ae Annual Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces the European Launch of DZUVEO by its Partner, Aguettant","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals Announces Divestment of DSUVIA\u00ae to Alora Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Alora Pharmaceuticals","pharmaFlowCategory":"D","amount":"$2.7 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA\u00ae to Alora Pharmaceuticals","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$26.3 million","upfrontCash":"Undisclosed","newsHeadline":"AcelRx Pharmaceuticals Announces Closing of Previously Announced Private Placement Priced At-The-Market Under Nasdaq Rules","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III"},{"orgOrder":0,"company":"AcelRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"AcelRx Receives IDE Approval for Niyad and Advances to a Single Registration Study","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Hematology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by AcelRx Pharmaceuticals
Niyad (a lyophilized formulation of nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
The net proceeds will be used to advance Niyad (nafamostat), an investigational broad-spectrum serine protease inhibitor with anticoagulant, anti-inflammatory, mucus clearing and potential anti-viral activities, towards an FDA approval.
Under the divestment, Alora will accelerate the commercialization of Dsuvia (sufentanil), a synthetic opioid analgesic formulation for the management of acute pain.
The divestment allows AcelRx to participate in the long-term value expected to be created by Alora as they expand the commercialization of Dsuvia (sufentanil citrate).
DSUVIA (sufentanil), an opioid analgesic, is indicated for use in adults for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
DZUVEO® (sufentanil sublingual tablet, 30 mcg), a novel sublingual approach to acute pain management, was designed to provide rapid analgesia via a non-invasive route and to eliminate high peak plasma levels and provide longer duration of action.
Dsuvia (sufentanil) is an opioid analgesic previously only marketed for IV and epidural anesthesia and analgesia, is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
DSUVIA, known as DZUVEO (sufentanil citrate) in Europe, is indicated for use in adults in certified medically supervised healthcare settings, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
DSUVIA (sufentanil sublingual tablet), known as DZUVEO® in Europe, is indicated for use in adultsfor the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.
Study found that Dzuveo (Sufentanil Citrate) lowered the opioid dose required by patients in the post-anesthesia care unit (PACU) by more than five-fold compared to standard intravenous opioid administration.